Day End Prices will be available on InvestorsLounge.com !


Abbott Laboratories (Pakistan) Limited (ABOT): Corporate analyst briefing takeaways – By JS Research

  • By: JS Global Capital Limited

  • - Published: Tuesday, 17 December 2024
Abbot.png
<p></p><ul><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">Abbott Laboratories (ABOT) conducted its corporate briefing today to discuss CY23 &amp; 9MCY24 results and outlook. To recall, the company reported earnings of Rs3.9bn (EPS: Rs40.34) during 9MCY24. We present key highlights from the session.</span></li></ul><ul><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">During 9MCY24, ABOT&rsquo;s sales revenue clocked in at Rs49.6bn, posting a growth of 20% YoY led by price adjustments. This increase was driven by 22% YoY growth in pharmaceutical segment, 13% YoY growth in nutritional segment, and 25%YoY growth in diagnostics segment.</span></li></ul><ul><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">Consequently, the gross margin improved by 8ppts ...

Similar Reports